目的 探讨海昆肾喜胶囊联合氢氯噻嗪片治疗慢性肾功能衰竭的临床疗效。方法 选取2014年6月—2018年6月在漯河市第三人民医院治疗的慢性肾功能衰竭患者82例，根据用药的差别分为对照组（41例）和治疗组（41例）。对照组口服氢氯噻嗪片，25 mg/次，1次/d；治疗组在对照组基础上口服海昆肾喜胶囊，0.44 g/次，3次/d。两组患者均治疗8周。观察两组患者临床疗效，同时比较治疗前后两组患者症候积分、SF-36量表、APACHEⅡ量表、肾功能和血清学指标。结果 治疗后，对照组和治疗组临床有效率分别为73.17%和95.12%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组症状积分均显著降低（P<0.05），且治疗组这些症候积分明显低于对照组（P<0.05）。治疗后，两组SF-36量表显著升高（P<0.05），APACHEⅡ量表积分明显降低（P<0.05），且治疗组SF-36和APACHEⅡ量表明显好于对照组（P<0.05）。治疗后，两组患者尿素氮（BUN）、血肌酐（SCr）、尿微量蛋白（U-MTB）明显降低（P<0.05），GFR显著升高（P<0.05），且治疗组肾功能明显好于对照组（P<0.05）。治疗后，两组患者血清胱抑素C（CysC）、β2-微球蛋白（β2-MG）、可溶性fms样酪氨酸激酶受体1（sFIt-1）、组织金属蛋白酶抑制因子-1（TIMP-1）水平明显降低（P<0.05），且治疗组这些血清学指标明显低于对照组（P<0.05）。结论 海昆肾喜胶囊联合氢氯噻嗪片治疗慢性肾功能衰竭可有效改善患者临床症状及肾功能，促进患者生活质量改善，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Haikun Shenxi Capsules combined with hydrochlorothiazide in treatment of chronic renal failure. Methods Patients (82 cases) with chronic renal failure in Luohe Third People's Hospital from June 2014 to June 2018 were divided into control (41 cases) and treatment (41 cases) groups according to different treatments. Patients in the control group were po administered with Hydrochlorthiazide Tablets, 25 mg/time, once daily. Patients in the treatment group were po administered with Haikun Shenxi Capsules on the basis of the control group, 0.44 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the symptom scores, SF-36 and APACHE Ⅱ scales, renal function and the serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 73.17% and 95.12% respectively, and there were differences between two groups (P<0.05). After treatment, the symptom scores in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the SF-36 scales in two groups were significantly increased (P<0.05), but APACHE Ⅱ scales were significantly decreased (P<0.05), the SF-36 and APACHE Ⅱ scales in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the BUN, SCr, U-MTB in two groups were significantly decreased (P<0.05), but GFR was significantly increased (P<0.05), and the renal function in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the serum CysC, β2-MG, sFIt-1 and TIMP-1 levels in two groups were significantly decreased (P<0.05), and these serological indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Haikun Shenxi Capsules combined with hydrochlorothiazide in treatment of chronic renal failure can effectively improve the clinical symptoms and renal function, and promote the improvement of life quality, which has a certain clinical application value.